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Background: Most patients with pancreatic cancer have non-resectable disease at the time of diagnosis and
usually die within 6–12 months. Despite indications in other solid tumors, the role of immunotherapy (IO) is
unknown for late stage, advanced pancreatic cancer.
Methods: Using the National Cancer Database (NCDB), cases of Stage IV pancreatic cancers diagnosed in
the period of 2014–2016 with at least 30-day follow up were retrospectively analyzed. The following clinical
demographics were included: age (younger than 70 vs. older than 70), sex (male vs. female), race (whites vs.
others), insurance (uninsured vs. insured), type of institution (academic vs. nonacademic), liver metastasis
(yes vs. no), lung metastasis (yes vs. no), external beam radiation (yes vs. no), systemic chemotherapy (yes
vs. no) and IO (yes vs. no). survival analysis was performed using Kaplan-Meier curves and Log-rank tests.
Multivariable Cox proportional hazard models and propensity score matching analysis were also utilized. A P
value <0.05 was considered significant.
Results: Among 25,596 eligible cases, 163 patients were treated with IO. A significant association between
the use of IO and several clinical demographics (age <70, academic institution, adenocarcinoma, lung
metastasis, radiation, chemotherapy) was noted. Chemotherapy was administered in 133 (82%) and 16,342
(64%) of cases in the IO and non-IO groups, respectively. Use of IO was associated with improved overall
survival (OS) in both univariate and multivariate analyses (P<0.0001 for each). Median OS (in months)
was 12.2 in the IO group vs. 5.8 in the non-IO group. Landmark analysis in the IO group showed 12 and
24-month survival of 51.0% and 20.0% respectively, as compared with 28.2% and 11.9% in the non-IO
group. Propensity score matching analysis also demonstrated a trend toward improved OS in IO group
(P=0.0753). Median survival was 12.2 and 8.9 months, respectively.
Conclusions: This retrospective data analysis using a large cancer database suggests that use of IO could
improve survival in patients with advanced pancreatic cancer. More studies will be needed in the future to
validate these results.
Keywords: Immunotherapy (IO); propensity score matching; pancreatic cancer; PD-1
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Introduction
Pancreatic carcinoma is one of the deadliest malignancies,
ranking third in cancer-related deaths in the United States
with projections to become the second leading cause by
2030 (1). The incidence of pancreatic cancer has been
steadily increasing over the years and in 2020 itself, nearly
57,600 incident cases are projected. In fact, similar numbers
have unfortunately been predicted for pancreatic cancerrelated mortality with approximately 47,050 estimated
deaths as well (2). The prognosis of pancreatic cancer
remains dismal. The overall 5-year survival rate is 9% with
an expected survival of less than one year (2,3). The low
survival rate is attributed to many factors, of which the late
presentation of many patients is likely the most important.
Due to the relative asymptomatic nature of the initial stages
of the disease, the majority of patients with pancreatic
cancer have metastatic disease upon diagnosis or disease
that has aggressively spread to common sites, such as the
liver or peritoneal cavity (3,4). Less than 20% of patients
present with localized, resectable tumors, and while surgical
resection is regarded as the only treatment for cure, most
cancers recur. Treatment options for advanced metastatic
disease are scarce. Chemotherapy remains a mainstay
treatment with palliative supportive care recognized as an
important adjunct (5).
Although no adequate therapy has been found for
advanced pancreatic cancer, immunotherapy (IO) may hold
promise. Optimism surrounds IO as a viable therapeutic
approach for the management of solid tumors. Recently,
phase III clinical trials have demonstrated the efficacy
of IO in the management of solid cancers (6). As a
result, the Food and Drug Administration has approved
pembrolizumab and nivolumab for head and neck cancer,
renal cancer, melanoma, and lung cancer (7,8). In pancreatic
cancer specifically, multiple small-sized studies and clinical
trials involving immune-based strategies are ongoing with
preliminary positive results (9,10). Although no conclusive
data has been established, a formal analysis has not been
conducted and the role of this form of therapy still remains
unknown without a convincing consensus. Because of this
cancer’s therapeutic resistance and the lack of definitive
studies, the utilization of IO in this patient population has
not been well-assessed. In addition, analyses regarding the
demographic characteristics and clinical factors associated
with and comparing patients who may or may not have
received IO have not been performed to date. The current
study was undertaken to perform such analysis as well

© Journal of Gastrointestinal Oncology. All rights reserved.

655

as investigate the impact of IO on the overall survival
(OS) of patients with advanced stage IV pancreatic
cancer. We present the following article in accordance
with the STROBE checklist. Available at: http://dx.doi.
org/10.21037/jgo-20-191.
Methods
Database and study population
This was a retrospective analysis of hospital-based data
obtained from the National Cancer Database (NCDB).
The NCDB is a joint project established in 1989 of the
Commission on Cancer (CoC) of the American College
of Surgeons and the American Cancer Society. Since its
inception, the NCDB has become one of the largest cancer
registries that comprises approximately 70% of cancer
cases in the United States from over 1,500 CoC-accredited
centers. It is one of the most commonly used sources to
track trends in cancer care. Data is collected on various
information, including patient factors, Charlson-Deyo
comorbidity scores, tumor characteristics, staging details,
surgical and adjuvant treatments, and clinical outcomes
(11,12). The CoC’s NCDB and the hospitals participating
in this database are the source of the de-identified data used
herein; they have not verified and are not responsible for
the statistical validity of the data analysis or the conclusions
derived by the investigators. This study was exempt from
review by the Institutional Review Board and patient
consent was waived due to the utilization of de-identified
data. This study is in accordance with the Declaration of
Helsinki (as was revised in 2013).
Patients diagnosed with stage IV pancreatic cancer
with at least a 30-day follow-up from January 1, 2014
to December 31, 2016 at CoC-accredited centers were
identified and included in the study. A vast majority
[23,795 of 25,596 (93%) in all groups, 152 of 163 (93%)
in IO group] had M1. Tumor metastatic stage was defined
based upon the American Joint Committee on Cancer 7th
edition staging manual. Patients were identified using the
appropriate International Classification of Diseases for
Oncology, 3rd edition (ICD-O-3) codes based on histology
and anatomic primary site. Demographic information
consisting of age, gender, race, insurance coverage, and
comorbidity along with hospital institution characteristics
were extracted from patients that met this criterion.
Comorbidity was evaluated using Charlson-Deyo scores.
Tumor characteristics involving the histology as well as
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primary and metastatic sites of lesions and treatments
utilized for therapeutic management (chemotherapy,
external beam radiation, IO) were recorded as well. The
NCDB does not identify specific therapy agents used for
treatment; instead the general utilization and receipt of
respective treatment modalities was logged. Information in
treatment was available via NCDB only for first-course of
therapy. Treatments after progression on the initial therapy
were not collected by NCDB.
Statistical analysis
Descriptive statistics of demographic, clinical, and treatment
characteristics were recorded as categorical variables.
Pearson χ2 tests were utilized to make comparisons. OS
was measured from the date of diagnosis to the time of last
follow-up or death. For better correlation with OS, the
study was restricted to patients with at least a 30-day followup. Univariate survival analysis was performed using Kaplan
Meier curves. Statistical comparisons of survival between
groups treated with and without IO were performed
with log-rank tests. Cox proportional hazards regression
modeling was used for multivariate survival analysis
according to IO treatment utilization adjusted for age, sex,
race, institution, insurance coverage, Charlson-Deyo score,
cancer histology, tumor primary and metastatic sites, and
treatment modalities. Because of the size difference between
the IO-positive and IO-negative cohorts, we also utilized
a propensity score analysis to account for and potentially
reduce the effects of potential biases and confounders in
our study (13). All statistical analyses were performed using
JMP software version 13 (SAS Institute, Inc., Cary, NC,
USA). Adjusted hazard ratios (HR) and 95% confidence
interval (CI) are reported, with P value <0.05 used to
indicate statistical significance.
Results
Population characteristics
A total of 25,596 cases met our inclusion criteria. Of these
cases, 163 (0.6%) patients were treated with IO. A significant
association between the use of IO and several clinical
demographics was noted. Patients treated with IO tended
to be <70 years old, receive care at an academic institution,
have adenocarcinoma with lung metastasis, and receive
radiation and chemotherapy for treatments. Chemotherapy
was administered in 133 (82%) and 16,342 (64%) of

© Journal of Gastrointestinal Oncology. All rights reserved.

cases in IO and non-IO groups, respectively. Tables 1
and 2 illustrate the summary statistics for demographic,
hospital, and clinical factors including multiagent
chemotherapy without and with propensity score matching.
Survival impact of IO
Use of IO was associated with improved OS in both
univariate and multivariate analyses (P<0.0001 for each)
(Table 3). Among the entire cohort, median OS (in months)
as measured by Kaplan-Meier was 12.2 in the IO group
vs. 5.8 in the non-IO group. Landmark analysis in the IO
group showed 12- and 24-month survival of 51.0% and
20.0% respectively, as compared with 28.2% and 11.9% in
the non-IO group (Figure 1). After adjusting for imbalanced
covariates among IO-treated and non-IO-treated cohorts,
propensity score matching analysis assessing receipt of IO
continued to demonstrate a trend toward improved OS in
the IO group (P=0.0753). Median survival was 12.2 and
8.9 months, respectively (Figure 2).
Discussion
Pancreatic carcinoma is an extremely lethal malignancy
that is especially difficult to treat. Only a small percentage
of the patient population can undergo surgical resection.
The majority of patients are diagnosed with advanced stage
IV unresectable disease and life expectancy is in months.
With traditional chemotherapeutic agents providing limited
survival advantage and in the absence of targeted agents, IO
has gained interest but the potential benefit of it remains
unknown. This nationwide analysis examined survival
outcomes for patients with unresected advanced pancreatic
cancer who received IO versus those who did not. The
results of this study suggest an OS benefit for IO (median
survival, 12.2 vs. 5.8 months).
There is a paucity of large clinical studies that specifically
address the efficacy of IO in advanced pancreatic cancer.
Despite lacking significant power and size, a few studies
have shown promising results. Beatty et al. investigated
co-stimulatory immunomodulatory CD 40 agonists in
21 patients with locally advanced or metastatic pancreatic
cancer. They demonstrated that this therapy with the
chemotherapeutic agent, gemcitabine, improved median
OS compared to gemcitabine alone (7.4 vs. 5.7 months).
One patient with metastatic hepatic lesions was even able to
undergo surgical resection after therapy reduced the tumor
size by 64% and eradicated all hepatic metastases (14). In
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Table 1 Clinical characteristics of cases selected for analysis
Variable
Total

Immunotherapy
Yes
163 (100%)

No
25,433 (100%)

Total
25,596 (100%)

Age

<0.0001

70+

44 (27%)

10,738 (42%)

10,782 (42%)

<70

119 (73%)

14,695 (58%)

14,814 (58%)

Male

86 (53%)

13,402 (53%)

13,488 (53%)

Female

77 (47%)

12,031 (47%)

12,108 (47%)

White

145 (89%)

20,754 (82%)

20,899 (82%)

Other

18 (11%)

4,679 (18%)

4,697 (18%)

Academic

87 (53%)

9,975 (39%)

10,062 (39%)

Other

76 (47%)

15,458 (61%)

15,534 (61%)

Yes

161 (99%)

24,800 (98%)

24,961 (98%)

No

2 (1%)

Sex

0.9867

Race

0.0156

Institution

0.0002

Insurance

0.3018
633 (2%)

635 (2%)

Charlson-Deyo score

0.3793

0–1

152 (93%)

23,222 (91%)

23,374 (91%)

2–3

11 (7%)

2,211 (9%)

2,222 (9%)

Histology
Adenocarcinoma
Other

0.0151
113 (69%)

19,666 (77%)

19,779 (77%)

50 (31%)

5,767 (23%)

5,817 (23%)

Liver metastasis

0.6513

Yes

120 (74%)

19,114 (75%)

19,234 (75%)

No

43 (26%)

6,319 (25%)

6,362 (25%)

Lung metastasis

0.0006

Yes

48 (29%)

4,814 (19%)

4,862 (19%)

No

115 (71%)

20,619 (81%)

20,734 (81%)

Radiation

<0.0001

Yes

19 (12%)

1,261 (5%)

1,280 (5%)

No

144 (88%)

24,172 (95%)

24,316 (95%)

Yes

133 (82%)

16,342 (64%)

16,475 (64%)

No

30 (18%)

9,091 (36%)

9,121 (6%)

42 (26%)

9,223 (36%)

9,265 (36%)

121 (74%)

16,210 (64%)

16,331 (64%)

Yes

115 (71%)

12,881 (51%)

12,996 (51%)

No

48 (29%)

12,552 (49%)

12,600 (49%)

Chemotherapy

<0.0001

Primary location
Pancreatic Head
Other

P value

0.0005

Multi-agent chemotherapy

<0.0001
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Table 2 Univariate and multivariate analyses for OS
Univariate

Variable

Multivariate

HR (95% CI)

P value

HR (95% CI)

P value

0.68 (0.67–0.70)

<0.0001

0.76 (0.74–0.78)

<0.0001

1.01 (0.95–1.07)

0.7576

0.98 (0.95–1.00)

0.0811

0.97 (0.94–1.01)

0.1548

0.96 (0.92–0.99)

0.0200

0.81 (0.79–0.83)

<0.0001

0.83(0.80–0.85)

<0.0001

0.99 (0.91–1.08)

0.8356

0.92 (0.84–1.01)

0.0710

0.72 (0.68–0.75)

<0.0001

0.80 (0.76–0.84)

<0.0001

0.73 (0.71–0.76)

<0.0001

0.64 (0.62–0.66)

<0.0001

0.89 (0.86–0.92)

<0.0001

0.83 (0.80–0.86)

<0.0001

0.85 (0.82–0.88)

<0.0001

0.83 (0.81–0.86)

<0.0001

0.91 (0.86–0.97)

0.0033

1.02 (0.96–1.09)

0.4821

0.55 (0.53–0.56)

<0.0001

0.53 (0.51–0.54)

<0.0001

0.97 (0.94–1.00)

0.0396

0.97 (0.94–1.00)

0.00394

0.60 (0.49–0.71)

<0.0001

0.69 (0.57–0.82)

<0.0001

Age
20–69 vs. 70+
Sex
Female vs. male
Race
Others vs. Whites
Institution
Academic vs. nonacademic
Insurance
Yes vs. no
Charlson-Deyo score
0–1 vs. 2–3
Histology
Others vs. adenocarcinoma
Liver metastasis
No vs. yes
Lung metastasis
No vs. yes
Radiation
Yes vs. no
Chemotherapy
Yes vs. no/unknown
Primary location
Pancreatic head vs. other
Immunotherapy
Yes vs. no/unknown

HR, hazard ratio; CI, confidence interval; OS, overall survival.

a phase I trial, 49 patients with advanced pancreatic cancer
received dendritic cell-based IO with gemcitabine with or
without lymphokine activated killer (LAK) IO. Patients
who received the combination treatment with LAK therapy
were noted to have prolonged survival (15). Both of these
studies utilized a combination of IO and chemotherapy
to treat cancer. It has been well-recognized that the
utilization of chemotherapy to prime the immune system
in preparation for IO can be advantageous against cancer.

© Journal of Gastrointestinal Oncology. All rights reserved.

The above studies confirm that the belief found in other
studies that chemo-IO can have synergistic effects that
improve OS outcomes (16-18). Our study also indicated
that most patients who receive IO also were treated with
chemotherapy (likely gemcitabine and protein-bound
paclitaxel), confirming that these therapies are being given
in combination due to their ability to enhance anti-tumor
immune responses in cancer.
Other clinical studies have also looked specifically at
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Table 3 Propensity score matched cases
Variable
Total

Immunotherapy
Yes

No

163 (100%)

163 (100%)

Total
326 (100%)

Age

1.000

70+

44 (27%)

44 (27%)

88 (27%)

<70

119 (73%)

119 (73%)

238 (73%)

Male

86 (53%)

82 (50%)

168 (52%)

Female

77 (47%)

81 (50%)

158 (48%)

White

145 (89%)

147 (90%)

292 (90%)

Other

18 (11%)

16 (10%)

34 (10%)

Academic

87 (53%)

86 (53%)

173 (53%)

Other

76 (47%)

77 (47%)

153 (47%)

Yes

161 (99%)

163 (99%)

324 (99%)

No

2 (1%)

0 (0%)

2 (1%)

Sex

0.6576

Race

0.7170

Institution

0.9116

Insurance

0.1560

Charlson-Deyo score

0.8215

0–1

152 (93%)

153 (94%)

305 (94%)

2–3

11 (7%)

10 (6%)

21 (6%)

Histology
Adenocarcinoma
Other

0.5423
113 (69%)

118 (72%)

231 (71%)

50 (31%)

45 (28%)

95 (29%)

Liver metastasis

0.2406

Yes

120 (74%)

129 (79%)

249 (76%)

No

43 (26%)

34 (21%)

77 (24%)

Lung metastasis

0.8091

Yes

48 (29%)

50 (31%)

98 (30%)

No

115 (71%)

113 (69%)

228 (70%)

Radiation

0.3586

Yes

19 (12%)

14 (9%)

33 (10%)

No

144 (88%)

149 (91%)

293 (90%)

Yes

133 (82%)

131 (80%)

264 (81%)

No

30 (18%)

32 (20%)

62 (19%)

42 (26%)

35 (21%)

77 (24%)

121 (74%)

128 (78%)

249 (76%)

Yes

115 (71%)

109 (67%)

224 (69%)

No

48 (29%)

54 (33%)

102 (31%)

Chemotherapy

0.7777

Primary location
Pancreatic head
Other

0.3614

Multi-agent chemotherapy

© Journal of Gastrointestinal Oncology. All rights reserved.

P value

0.4735
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Survival Probability

1.0

Immunotherapy median OS
Yes
12.2 months
No
5.8 months

0.8

Log-rank P<0.0001
Wilcoxon P<0.0001

0.6
0.4
0.2
0.0

0

10

20
30
Months

40

50

Year
OS%/Number at risk

0

1

2

3

Immunotherapy-Yes

100%/163

51.0%/70

20.0%/22

14.1%/2

Immunotherapy-No

100%/25433

28.2%/6191 11.9%/1794 6.5%/378

Strengths and limitations

Figure 1 Kaplan-Meier curves of OS for patients with stage IV
pancreatic cancer treated with or without IO. IO, immunotherapy;
OS, overall survival.

Survival Probability

1.0

Immunotherapy median OS
Yes
12.2 months
No
8.9 months

0.8

Log-rank P=0.0753
Wilcoxon P=0.0065

0.6
0.4
0.2
0.0

0

5

10

15

20
25
Months

30

35

40

45

Year
OS%/Number at risk

0

1

2

3

Immunotherapy-Yes

100%/163

51.0%/70

20.0%/22

14.1%/2

Immunotherapy-No

100%/163

37.9%/57

21.2%/20

9.3%/7

Figure 2 Kaplan-Meier curves of OS for patients with stage IV
pancreatic cancer treated with or without IO after propensity score
matching. IO, immunotherapy; OS, overall survival.

the use of IO in stage IV pancreatic cancer patients and
reported OS benefits similar to our study. One study in
which 15 of 20 patients had stage IV pancreatic cancer
assessed the efficacy of adoptive IO utilizing dendritic cells
and cytotoxic T lymphocytes. The combinative IO resulted
in greater than 20% 1-year survival for these patients. Five
patients were found to have stable disease and one of these

© Journal of Gastrointestinal Oncology. All rights reserved.

patients with liver metastasis maintained stable disease for
6 months. Most impressively, one patient who had multiple
lung metastases experienced a complete response that lasted
>5 years (19). Similarly, Lin et al. found comparable results
in patients with unresectable stage IV pancreatic cancer.
They noted a significant survival benefit with a higher
median OS when cancer ablation treatment was combined
with natural killer cell therapy (20). Our study which
includes the largest investigation and analysis of stage IV
pancreatic cancer patients to date corroborates and validates
these studies in demonstrating an OS benefit in patients
who received IO.

This study was powered by a large sample size
representative of most cancer cases across the United
States. It provided sufficient data to quantify trends and
the impact of IO in patients with stage IV pancreatic
cancer—an investigation that has been difficult to assess
from previous studies and trials. Despite these strengths,
the study still has limitations inherent to its retrospective
nature and use of a database like the NCDB. One major
limitation involves selection bias. Our study found that
the patients in the cohort that received IO were younger,
relatively healthier with less comorbidity, and likely treated
through clinical trials at academic facilities than those who
did not receive IO. This is very similar to another study that
investigated the role of adjuvant chemo-IO in pancreatic
cancer (18). While we attempted to minimize selection bias
through propensity score matching analysis, we understand
that it cannot be completely nullified. We also realize this
along with the small size of the IO-treated patient cohort
in comparison to the opposing group may have affected
this study’s external validity. Limitations associated with
the NCDB include possible erroneous coding entries in
the dataset and the inability to assess data relating to other
endpoints of interest such as treatment toxicity, quality of
life, and progression-free survival. Moreover, the NCDB
generalized treatment information and did not provide the
specific treatment agents used within cases. This limited our
ability to further compare outcomes among various known
IO agents.
Conclusions
To our knowledge, this study is the largest investigation to
assess the trends and outcomes of patients with advanced,
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stage IV pancreatic cancer who may or may not have
received IO. Using the NCDB, this analysis demonstrated a
survival benefit with improved OS in patients who received
IO. Given the lack of available definitive treatment for
advanced pancreatic cancer, our study suggests that IO
treatment should be considered and ultimately implemented
in this patient population. Our findings warrant the need for
future prospective, randomized clinical trials that evaluate
outcomes related to long-term survival, quality of life, and
overall efficacy of IO for stage IV pancreatic cancer.
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